pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
The role of pERK, pAKT and p53 as biomarkers in patients with advanced pancreatic cancer has not yet been defined.
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 August 2014
|
| In: |
BMC cancer
Year: 2014, Jahrgang: 14 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-14-624 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-14-624 Verlag, lizenzpflichtig, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-624 |
| Verfasserangaben: | Steffen Ormanns, Jens T. Siveke, Volker Heinemann, Michael Haas, Bence Sipos, Anna Melissa Schlitter, Irene Esposito, Andreas Jung, Rüdiger P. Laubender, Stephan Kruger, Ursula Vehling-Kaiser, Cornelia Winkelmann, Ludwig Fischer von Weikersthal, Michael R. Clemens, Thomas C. Gauler, Angela Märten, Michael Geissler, Tim F. Greten, Thomas Kirchner and Stefan Boeck |
| Zusammenfassung: | The role of pERK, pAKT and p53 as biomarkers in patients with advanced pancreatic cancer has not yet been defined. |
|---|---|
| Beschreibung: | Gesehen am 09.09.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-14-624 |